Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

This is a phase 2, multicenter, single arm, 2 cohort study to assess the safety, efficacy
and pharmacokinetics of AMG 337 in MET amplified Gastric/esophageal adenocarcinoma or other
solid tumors. Approximately 140 subjects will be enrolled to either Cohort 1 (subjects with
MET amplified G/E adenocarcinoma with measurable tumor) or Cohort 2 (subjects with MET
amplified solid tumors with measurable tumor/up to 10 subjects with MET amplified G/E
adenocarcinoma with non-measurable tumor/up to 10 subjects who have received prior MET
antibody therapy). All subjects will self-administer AMG 337 300 mg daily until disease
progression or other protocol specified end of treatment criteria is met.

Tumor tissue, biomarkers, Pharmacokinetics and Patient reported Outcomes will all be
assessed.

Tumor assessment by RECIST 1.1 will be followed during study treatment.

Inclusion Criteria:

- Able to daily self-administer AMG 337 orally as a whole capsule

- Male or female 18 years of age or over.

- Pathologically confirmed advanced G/GEJ/E adenocarcinoma (Cohort 1) or other solid
tumor (Cohort 2) for which subject has received prior therapy for advanced disease,
for which no standard therapy exists, or subject refuses standard therapy

- Tumor MET amplified by protocol-specified centralized testing.

- Measurable disease per RECIST 1.1 guidelines. Cohort 2 may include up to 10 subjects
with advanced MET amplified, G/GEJ/E adenocarcinoma with non-measurable tumor per
RECIST v1.1

- (ECOG) Performance Status of 0, 1 or 2

Exclusion Criteria:

- Known central nervous system metastases

- Candidate for curative surgery or definitive chemoradiation

- Peripheral edema > grade 1

- Persistent gastric outlet obstruction, complete dysphagia or are dependent upon
jejunostomy for feeding. Significant gastrointestinal disorder(s) that in the opinion
of the Investigator may influence drug absorption

- Acute Hepatitis B. Chronic Hepatitis B eligible if condition is stable and, in the
opinion of the investigator or Amgen physician, if consulted, would not pose a risk
to subject safety

- Detectable Hepatitis C virus (indicative of active Hepatitis C)

- Currently receiving any anti-tumor treatments, or less than 14 days prior to
enrollment since ending anti-tumor treatment

- Prior treatment with small molecule inhibitors of the MET pathway.

Other protocol defined inclusion criteria may apply.